ORGENESIS INC (ORGS)
US68619K2042 - Common Stock
Orgenesis Provides Year End Business Update
Major transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera Secured a $2.3 million investment...
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell...
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell...
Orgenesis Inc. Announces $2.3 Million Private Placement
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell...
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and...
Orgenesis to buy stake in Octomera for advancing immuno-oncology portfolio (NASDAQ:ORGS)
Orgenesis acquires Metalmark Capital Partners' stake in Octomera, gaining full ownership.
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell...
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...
Orgenesis Provides Business Update for the Third Quarter of 2023
Advances rollout of POCare Platform and POCare Therapies...
Orgenesis announces pricing of $1.1M registered direct offering (NASDAQ:ORGS)
Orgenesis (ORGS) said on Wednesday that it had entered into a securities purchase agreement with a single institutional investor. Shares of ORGS jumped 8.7% in
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another busy day of trading as we go over the biggest pre-market stock movers worth watching on Tuesday morning!
Orgenesis Announces Withdrawal of Proposed Public Offering
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...
Orgenesis Announces Proposed Underwritten Public Offering
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...